Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 95 of the 97 references it cites were found in a registry or an index; 29 of the 59 sources its claims cite were checked for support.

Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations

Open access

Abstract

AbstractMitochondria are organelles that govern energy supply and control cell death. Mitochondria also express bacterial features, such as the presence of inner membrane cardiolipin and a circular genome rich in hypomethylated CpG motifs. While mitochondrial extrusion by damaged organs or activated cells is thought to trigger innate immunity, it is unclear whether extracellular mitochondria also stimulate an adaptive immune response. We describe the development of novel assays to detect autoantibodies specific to two distinct components of the mitochondrion: the mitochondrial outer membrane and mitochondrial DNA. Antibodies to these two mitochondrial constituents were increased in both human and murine systemic lupus erythematosus (SLE), compared to controls, and were present at higher levels than in patients with antiphospholipid syndrome or primary biliary cirrhosis. In both bi- and multi-variate regression models, antibodies to mitochondrial DNA, but not whole mitochondria, were associated with increased anti-dsDNA antibodies and lupus nephritis. This study describes new and optimized methods for the assessment of anti-mitochondrial antibodies, and demonstrates their presence in both human and murine SLE. These findings suggest that different mitochondrial components are immunogenic in SLE, and support the concept that extracellular mitochondria may provide an important source of circulating autoantigens in SLE.

Overview

CoChat Summary

TL;DR

This study developed ELISAs for autoantibodies against whole mitochondria (AwMA) and mitochondrial DNA (AmtDNA) and found both elevated in human and murine SLE. AmtDNA, but not AwMA, was associated with increased anti-dsDNA antibodies and lupus nephritis.

Key findings

  • AwMA and AmtDNA were increased in human SLE (n = 175) versus healthy controls (n = 43); AmtDNA was not increased in APS (n = 12) or PBC (n = 12), while AwMA was also elevated in APS/PBC but at lower levels than in SLE. Both antibody types were also elevated in a murine SLE model (SLE n = 12, control n = 8).
  • AmtDNA was associated with increased anti-dsDNA antibodies (OR 3.34, 95% CI 1.22–9.16, p = 0.02) and lupus nephritis (OR 4.45, 95% CI 1.50–13.20, p = 0.007); both associations remained significant in multivariate models (p = 0.01 for both). AwMA was not associated with clinical outcomes.
  • AwMA correlated with AmtDNA in SLE patients (rs = 0.23, p = 0.003) but not healthy controls (rs = 0.15, p = 0.33), and AwMA did not correlate with anti-HSP60 or anti-cardiolipin.
  • Assay performance: AwMA sensitivity 0.58, specificity 0.88, AUC 0.80; AmtDNA sensitivity 0.63, specificity 0.74, AUC 0.71. Using cutoffs, 101/175 (57.71%) SLE patients were AwMA-positive and 110/175 (62.86%) were AmtDNA-positive.

Methods

  • Mitochondria were isolated from mouse liver or Hep-G2 cells and purified by Percoll gradient; mtDNA was extracted by alkaline lysis. Direct ELISAs were developed using intact mitochondria as coating antigen for AwMA and protamine-sulfate-pre-coated plates with mtDNA for AmtDNA.
  • Human sera included 175 SLE patients, 43 healthy controls, 12 APS patients, and 12 PBC patients; murine SLE was induced in C57BL/6J mice by β2GPI/LPS immunizations. Clinical data included anti-dsDNA by Farr assay and anti-cardiolipin by ELISA.
  • Associations were assessed with Spearman correlations, Wilcoxon/Kruskal-Wallis/ANOVA tests, and bivariate/multivariate logistic regression; cutoffs were determined by Youden’s index with bootstrap confidence intervals.

Limitations

  • Stated in the paper: findings require confirmation in an independent cohort and a larger lupus population over time; AwMA may also recognize other membrane-bound microparticles or cells; the role of oxidation on mtDNA recognition could not be tested because isolated mtDNA spontaneously oxidizes; the study focused on IgG only; whether AwMA are pathogenic initiators or consequences remains unknown; and the mitochondrial antigen(s) recognized in the AwMA assay are unidentified.
  • Evident from the text: the human SLE cohort was cross-sectional and all female (Table 2), which limits causal/temporal inference and may affect generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41598-019-40900-3

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Assessment of the mitochondrial preparations. (a) Mitochondria were isolated from either mouse liver or human Hep-G2 cell line by differential centrifugations and further purified by ultracentrifugation against Percoll gradient. Alkaline lysis was performed to retrieve mtDNA. Pure mitochondria or mtDNA were used as coating antigens in direct ELISAs. (b) Cytoplasmic (C), nuclear (N) and mitochondrial (M) markers were assessed by western blotting in murine (left) and human (right) mitochondrial preparations (25 µg protein per lane). Results are representative of three distinct preparations. Blots separated by dashed lines are non-contiguous but from same membrane. Blots separated by full lines were performed on distinct membranes; (c) Functionality of murine mitochondria was determined by measurement of the oxygen consumption rate (OCR) of 10 µg mitochondria treated successively with 2 µM rotenone, 10 mM succinate, 40 µM antimycin A and 100 µM N,N,N’,N’-Tetramethyl-p-phenylenediamine (TMPD) along with 10 mM ascorbate (Asc). (d) The hydrodynamic size of the murine mitochondria was determined using zetasizer nano ZS (n = 3, left panel) and their morphology was visualized by electron microscopy (right panel). Inner membrane (black arrowhead), outer membrane (white arrowhead), cristae (black arrow), mitochondrial matrix (white arrow) are presented (scale bar account for 500 nm); (e) Size representation of purified murine mitochondria using high sensitivity-flow cytometry. Double-positive mitochondria (Mitotracker+ TOMM22+) were used for quantification. Silica beads were used to determine 100–1000 nm size scale. Data are mean ± SD. Anti-A: antimycin A; CytC: cytochtome C; FSC: forward scatter; Mito: mitochondria PCNA: proliferating cell nuclear antigen; SSC: side scatter; Total: total starting material; TOMM22: translocase of the outer mitochondrial membrane; VDAC: voltage-dependent anion channel.
Figure 1 Assessment of the mitochondrial preparations. (a) Mitochondria were isolated from either mouse liver or human Hep-G2 cell line by differential centrifugations and further purified by ultracentrifugation against Percoll gradient. Alkaline lysis was performed to retrieve mtDNA. Pure mitochondria or mtDNA were used as coating antigens in direct ELISAs. (b) Cytoplasmic (C), nuclear (N) and mitochondrial (M) markers were assessed by western blotting in murine (left) and human (right) mitochondrial preparations (25 µg protein per lane). Results are representative of three distinct preparations. Blots separated by dashed lines are non-contiguous but from same membrane. Blots separated by full lines were performed on distinct membranes; (c) Functionality of murine mitochondria was determined by measurement of the oxygen consumption rate (OCR) of 10 µg mitochondria treated successively with 2 µM rotenone, 10 mM succinate, 40 µM antimycin A and 100 µM N,N,N’,N’-Tetramethyl-p-phenylenediamine (TMPD) along with 10 mM ascorbate (Asc). (d) The hydrodynamic size of the murine mitochondria was determined using zetasizer nano ZS (n = 3, left panel) and their morphology was visualized by electron microscopy (right panel). Inner membrane (black arrowhead), outer membrane (white arrowhead), cristae (black arrow), mitochondrial matrix (white arrow) are presented (scale bar account for 500 nm); (e) Size representation of purified murine mitochondria using high sensitivity-flow cytometry. Double-positive mitochondria (Mitotracker+ TOMM22+) were used for quantification. Silica beads were used to determine 100–1000 nm size scale. Data are mean ± SD. Anti-A: antimycin A; CytC: cytochtome C; FSC: forward scatter; Mito: mitochondria PCNA: proliferating cell nuclear antigen; SSC: side scatter; Total: total starting material; TOMM22: translocase of the outer mitochondrial membrane; VDAC: voltage-dependent anion channel.CC BY · PubMed Central
Figure 2 Antibodies targeting mitochondrial antigens are produced in a murine model of SLE. (a) Elevated levels of anti-whole mitochondria antibodies (AwMA) were detected by direct ELISA in sera (1:150) from an inducible murine model of systemic lupus erythematosus (SLE) compared to control mice. An isotype-matched monoclonal mouse anti-translocase of the outer mitochondrial membrane 22 (TOMM22) antibody (clone IC9-2. 4 µg/mL) was included as a positive assay control (dotted line). (Control: N = 8, SLE: N = 12, Student’s t-test); (b) Lipid peroxidation following in-vitro oxidation of the mitochondria by 500 µM tert-buthyl hydroperoxide (TBHP) was quantified by thiobarbituric reactive substances (TBARS) assay (N = 3, Wilcoxon test); (c) Protein oxidation was determined by carbonyl assay (n = 6, Wilcoxon test); (d) The effect of oxidation of mitochondrial epitopes on their recognition by serum AwMA (1:20) was assessed by direct ELISA, using either native (grey symbols) or oxidized mitochondria (black symbols) as coating antigens (N = 13, two-way ANOVA with multiple comparisons; Sidak’s correction). All experiment presented in the figure were performed using mouse mitochondria. Data are mean ± SD. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001.
Figure 2 Antibodies targeting mitochondrial antigens are produced in a murine model of SLE. (a) Elevated levels of anti-whole mitochondria antibodies (AwMA) were detected by direct ELISA in sera (1:150) from an inducible murine model of systemic lupus erythematosus (SLE) compared to control mice. An isotype-matched monoclonal mouse anti-translocase of the outer mitochondrial membrane 22 (TOMM22) antibody (clone IC9-2. 4 µg/mL) was included as a positive assay control (dotted line). (Control: N = 8, SLE: N = 12, Student’s t-test); (b) Lipid peroxidation following in-vitro oxidation of the mitochondria by 500 µM tert-buthyl hydroperoxide (TBHP) was quantified by thiobarbituric reactive substances (TBARS) assay (N = 3, Wilcoxon test); (c) Protein oxidation was determined by carbonyl assay (n = 6, Wilcoxon test); (d) The effect of oxidation of mitochondrial epitopes on their recognition by serum AwMA (1:20) was assessed by direct ELISA, using either native (grey symbols) or oxidized mitochondria (black symbols) as coating antigens (N = 13, two-way ANOVA with multiple comparisons; Sidak’s correction). All experiment presented in the figure were performed using mouse mitochondria. Data are mean ± SD. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001.CC BY · PubMed Central
Figure 3 Detection of anti-mitochondrial antibodies in SLE patients and specificity of the assay. (a) Increased amounts of anti-whole mitochondria antibodies (AwMA) were detected by direct ELISA in sera (1:150) from systemic lupus erythematosus (SLE), anti-phospholipid syndrome (APS) and primary biliary cirrhosis (PBC) patients. Healthy: N = 43. SLE: N = 175. APS: N = 12, PBC: N = 12. The dotted line corresponds to the cutoff value as determined by Youden’s Index (see Table 5). Kruskal-Wallis test with multiple comparisons to healthy donors; Dunn’s correction. (b) No significant differences were detected by direct ELISA when either murine (Mm, gray symbols) or human mitochondria (Hs, black symbols) were used as coating antigens to detect AwMAs in control and SLE patient sera (1:100). Two-way ANOVA. (c) AwMA binding to coating mitochondria is inhibited in presence of mitochondria (filled circles) but not by red blood cells microparticles (filled squares). Two-way repeated measures ANOVA with multiple comparison (Dunnett’s correction) to signals detected without competitors (i.e. 100%). Experiments presented in panels 3 a and 3 c were performed using mouse mitochondria, the experiment presented in panel 3 b was performed in parallel on murine and human mitochondria. Data are mean ± SD. Not significant (ns): p > 0.05. *p < 0.05. ***p < 0.001. ****p < 0.0001. Hs: Homo sapiens; Mm: Mus musculus.
Figure 3 Detection of anti-mitochondrial antibodies in SLE patients and specificity of the assay. (a) Increased amounts of anti-whole mitochondria antibodies (AwMA) were detected by direct ELISA in sera (1:150) from systemic lupus erythematosus (SLE), anti-phospholipid syndrome (APS) and primary biliary cirrhosis (PBC) patients. Healthy: N = 43. SLE: N = 175. APS: N = 12, PBC: N = 12. The dotted line corresponds to the cutoff value as determined by Youden’s Index (see Table 5). Kruskal-Wallis test with multiple comparisons to healthy donors; Dunn’s correction. (b) No significant differences were detected by direct ELISA when either murine (Mm, gray symbols) or human mitochondria (Hs, black symbols) were used as coating antigens to detect AwMAs in control and SLE patient sera (1:100). Two-way ANOVA. (c) AwMA binding to coating mitochondria is inhibited in presence of mitochondria (filled circles) but not by red blood cells microparticles (filled squares). Two-way repeated measures ANOVA with multiple comparison (Dunnett’s correction) to signals detected without competitors (i.e. 100%). Experiments presented in panels 3 a and 3 c were performed using mouse mitochondria, the experiment presented in panel 3 b was performed in parallel on murine and human mitochondria. Data are mean ± SD. Not significant (ns): p > 0.05. *p < 0.05. ***p < 0.001. ****p < 0.0001. Hs: Homo sapiens; Mm: Mus musculus.CC BY · PubMed Central
Figure 4 Antibodies targeting mitochondrial DNA in SLE. (a) Anti-mitochondrial DNA antibodies (AmtDNA) are measured by direct ELISA in sera (1:50) from a mouse model of systemic lupus erythematosus (SLE) and control mice (Control: N = 8, SLE: N = 12, Student’s t-test). An isotype-matched monoclonal mouse anti-DNA antibody (clone 35I9 DNA, 10 µg/mL) was included as a positive assay control (dotted line). (b) Elevated levels of AmtDNA are observed in sera (1:150) from SLE but not from anti-phospholipid syndrome (APS) or primary biliary cirrhosis (PBC) patients. Healthy: N = 43. SLE: N = 175. APS: N = 12. PBC: N = 12. The dotted line corresponds to the cutoff value as determined by Youden’s index (see Table 5). Kruskal-Wallis test with multiple comparisons to controls/healthy donors; Dunn’s correction). All experiment presented in the figure were performed using mouse mtDNA. Data are mean ± SD. Not significant (ns): p > 0.05. ***p < 0.001. PBC: primary biliary cirrhosis.
Figure 4 Antibodies targeting mitochondrial DNA in SLE. (a) Anti-mitochondrial DNA antibodies (AmtDNA) are measured by direct ELISA in sera (1:50) from a mouse model of systemic lupus erythematosus (SLE) and control mice (Control: N = 8, SLE: N = 12, Student’s t-test). An isotype-matched monoclonal mouse anti-DNA antibody (clone 35I9 DNA, 10 µg/mL) was included as a positive assay control (dotted line). (b) Elevated levels of AmtDNA are observed in sera (1:150) from SLE but not from anti-phospholipid syndrome (APS) or primary biliary cirrhosis (PBC) patients. Healthy: N = 43. SLE: N = 175. APS: N = 12. PBC: N = 12. The dotted line corresponds to the cutoff value as determined by Youden’s index (see Table 5). Kruskal-Wallis test with multiple comparisons to controls/healthy donors; Dunn’s correction). All experiment presented in the figure were performed using mouse mtDNA. Data are mean ± SD. Not significant (ns): p > 0.05. ***p < 0.001. PBC: primary biliary cirrhosis.CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 2 Not valid · 13 Not checked · 84 Own results and interpretations

62 more claims

Create a free account to see all 111 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 30
  • It may state two separate claims as one. 16
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 97 references

Cited by

See all 75

Metadata

Authors
Becker, Y., Loignon, R.-C., Julien, A.-S., Marcoux, G., Allaeys, I., Lévesque, T., Rollet-Labelle, E., Benk-Fortin, H., Cloutier, N., Melki, I., Eder, L., Wagner, É., Pelletier, M., Hajj, H. E., Tremblay, M.-È., Belleannée, C., Hébert, M.-J., Dieudé, M., Rauch, J., Fortin, P. R., & Boilard, E.
Affiliations
  • Centre de recherche du CHU de Québec-Université Laval (CA)
  • Université Laval (CA)
  • University of Toronto (CA)
  • Centre hospitalier universitaire de Québec (CA)
  • McGill University Health Centre (CA)
Corresponding author
Fortin, Paul R.
Venue
Scientific Reports
Published
2019-03-14
Volume
9
Issue
1
Pages
4530-4530
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2921439506
Cited by
75
References
97
Citations by year
2026: 8 · 2025: 14 · 2024: 10 · 2023: 11 · 2022: 13 · 2021: 7 · 2020: 8 · 2019: 4
FWCI
6.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • McGill University
  • Australian Government
  • Canadian Blood Services
  • Arthritis Society (225638)
  • Canadian Institutes of Health Research (PJT159652)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
systemic lupus erythematosus, mitochondrial outer membrane, lupus nephritis, anti-dsDNA antibodies, extracellular mitochondria, autoantigens, cardiolipin, CpG motifs, murine lupus model, antiphospholipid syndrome, primary biliary cirrhosis
MeSH terms
Adult, Aged, Animals, Antibodies, Antinuclear, Autoantibodies, Disease Models, Animal, DNA, Mitochondrial, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Mitochondria, Odds Ratio, Mitochondrial Proteins, Mice, Young Adult, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. https://app.cochat.ai/papers/10.1038/s41598-019-40900-3
The paper
Becker, Y., Loignon, R.-C., Julien, A.-S., Marcoux, G., Allaeys, I., Lévesque, T., Rollet-Labelle, E., Benk-Fortin, H., Cloutier, N., Melki, I., Eder, L., Wagner, É., Pelletier, M., Hajj, H. E., Tremblay, M.-È., Belleannée, C., Hébert, M.-J., Dieudé, M., Rauch, J., . . . Boilard, E. (2019). Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Scientific Reports. https://doi.org/10.1038/s41598-019-40900-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.